The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines.
Sullivan
Patrick W
PW
Pharmaceutical Outcomes Research Program, University of Colorado School of Pharmacy, Denver, CO 80262, USA. Patrick.Sullivan@UCHSC.edu
Nichol
Michael B
MB
D001499:Bayes Theorem; D003362:Cost-Benefit Analysis; D003627:Data Interpretation, Statistical; D039563:Histamine H1 Antagonists, Non-Sedating / Q000191:economics*; D006801:Humans; D017336:Loratadine / Q000191:economics*; D008329:Managed Care Programs / Q000191:economics; D008484:Medicaid / Q000191:economics; D009010:Monte Carlo Method; D004366:Nonprescription Drugs / Q000191:economics*
D039563:Histamine H1 Antagonists, Non-Sedating; D004366:Nonprescription Drugs; D017336:Loratadine